New Zealand Data Sheet
Lasix and Lasix High Dose- furosemide (frusemide)
lasix-lasix-high-dose-ccdsv12-dsv17-20jun22 Page 7
Furosemide (Frusemide) should be used with care, especially in the initial stages, in patients with
impairment of micturition (e.g. prostatic hypertrophy). Urinary outflow must be secured. In
patients with a partial obstruction of urinary outflow (e.g. in patients with bladder-emptying
disorders, prostatic hyperplasia or narrowing of the urethra), increased production of urine may
provoke or aggravate complaints. Thus, these patients require careful monitoring.
Particularly careful monitoring is required in patients with gout, patients with partial obstruction
of urinary outflow, in patients with hypotension or at risk from hypotension (e.g. patients with
significant stenoses of the coronary arteries or of the blood vessels supplying the brain) in patients
with latent or manifest diabetes mellitus, in patients with hepatorenal syndrome or in patients with
hypoproteinaemia (e.g. associated with nephrotic syndrome). Dose titration, especially in this
latter case, is required. In premature infants, there is the possible development of
nephrocalcinosis/nephrolithiasis and therefore renal function must be monitored and renal
ultrasonography performed. In premature infants furosemide (frusemide) administered during the
first weeks of life may increase the risk of persistence of Botallo’s duct.
As with any effective diuretic, electrolyte depletion may occur during therapy, especially in
patients receiving higher doses and a restricted salt intake. All patients receiving Lasix therapy
should be observed for signs of fluid or electrolyte imbalance; namely hyponatraemia,
hypochloraemic alkalosis, and hypokalaemia. Periodic determinations of serum electrolytes to
detect a possible imbalance should be performed at appropriate intervals, as well as creatinine,
blood urea and CO
2
content determinations. This is particularly important when the patient is at
high risk of developing electrolyte imbalances (eg. receiving parenteral fluids) or in case of
significant additional fluid loss such as vomiting, diarrhoea and intense sweating. Warning signs
of an imbalance, irrespective of cause include dryness of mouth, thirst, weakness, lethargy,
drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria,
tachycardia, arrhythmia, and gastrointestinal disturbances such as nausea and vomiting.
Hypovolaemia or dehydration as well as any significant electrolyte and acid-base disturbances
must be corrected. This may require temporary discontinuation of Lasix.
During long-term therapy, a high potassium diet is recommended. Potassium supplements may be
required, especially when high doses are used for prolonged periods. Particular caution with
potassium is necessary when the patient is on digitalis glycosides, potassium depleting steroids or
in the case of infants and children. Potassium supplementation, diminution in dose, or
discontinuation of furosemide (frusemide) therapy may be required.
Periodic checks on urine and blood glucose should be made in diabetics and even those suspected
of latent diabetes when receiving Lasix. Increases in blood glucose and alterations in glucose
tolerance tests with abnormalities of the fasting and 2-hour post prandial sugar have been
observed, and rare cases of precipitation of diabetes mellitus have been reported.
Lasix may lower calcium levels, and rare cases of tetany have been reported. Accordingly,
periodic serum calcium levels should be obtained.
In children, urge to defecate, complaints of abdominal pain and cramping have been reported after
IV furosemide (frusemide). An association of these symptoms with a low serum calcium and/or a
low calcium/protein ratio is possible.